$5750 | Single User
$11500 | Site License
$17250 | Enterprise License

Renal cell carcinoma - Market Insights, Epidemiology and Market Forecast – 2025 [Report Updated: 10-10-2017]

Published by Delve Insight: 10 Oct 2017 | 139151 | In Stock

Introduction

DelveInsight’s “Renal cell carcinoma - Market Insights, Epidemiology and Market Forecast - Market Insights, Epidemiology and Market Forecast – 2025” report provides an overview of the disease and in depth research related to Renal cell carcinoma - Market Insights, Epidemiology and Market Forecast for the 7MM (United States, Germany, France, Italy, Spain and UK) for the study period undertaken from 2015-2025.

This report provides understanding of the patients affected, diagnosed patterns, treatment trends, unmet medical needs and current developments for Renal cell carcinoma - Market Insights, Epidemiology and Market Forecast. It enables understanding of the historical and forecasted epidemiological data for the diagnosed prevalent cases of Renal cell carcinoma - Market Insights, Epidemiology and Market Forecast for 7 major markets. The market outlook also provides understanding of country specific revenue and share by analyzing performance of the current therapies and thorough potential uptake of new products. Additionally, the Report highlights the frontrunners, the drivers and barriers for the Renal cell carcinoma - Market Insights, Epidemiology and Market Forecast market, as well as treatment algorithm, current treatments & advancements are included.

The chapters including marketed products highlights the advantages and disadvantages associated with therapies associated with Renal cell carcinoma - Market Insights, Epidemiology and Market Forecast, providing an in-depth analysis of emerging therapies which will create an impact through their launch.

According to DelveInsight, the forecasted patient population of Renal cell carcinoma - Market Insights, Epidemiology and Market Forecast for the year 2025 will be XX, increasing at a CAGR of XX% from 2015 to 2025 and the Renal cell carcinoma - Market Insights, Epidemiology and Market Forecast 7MM market size is estimated to be USD XX by 2025. The DelveInsight Report will help in enhanced understanding of the Renal cell carcinoma - Market Insights, Epidemiology and Market Forecast market from inside out, with transparency into the calculated patient forecasting data and estimated market size.

Key Coverage

• Understanding historical and forecasted epidemiological data for Renal cell carcinoma - Market Insights, Epidemiology and Market Forecast covering 7MM from 2015-2025.

• Segment level epidemiology and market split for Renal cell carcinoma - Market Insights, Epidemiology and Market Forecast.

• The thorough assessment of competitors, market, current trends & treatments along with upcoming treatments for Renal cell carcinoma - Market Insights, Epidemiology and Market Forecast.

• The Report also covers the market size for 7MM (United States, EU 5 (Germany, Spain, Italy, France and United Kingdom) and Japan) from 2015-2025 and detailed historical and forecasted Renal cell carcinoma - Market Insights, Epidemiology and Market Forecast market trends.

• Thorough market distribution based on market share for Renal cell carcinoma - Market Insights, Epidemiology and Market Forecast.

Reasons to buy:

• The report will help in developing business strategies by understanding trends shaping and driving the Renal cell carcinoma - Market Insights, Epidemiology and Market Forecast market.

• To understand the future market competition in the Renal cell carcinoma - Market Insights, Epidemiology and Market Forecast market and Insightful review of the key market drivers and barriers.

• Organize sales and marketing efforts by identifying the best opportunities for Renal cell carcinoma - Market Insights, Epidemiology and Market Forecast in US, Europe (Germany, Spain, Italy, France and United Kingdom) and Japan.

• Identification of strong upcoming players in market will help in devising strategies that will help in getting ahead of competitors.

Table of Contents
for Renal cell carcinoma - Market Insights, Epidemiology and Market Forecast – 2025 [Report Updated: 10-10-2017]

  • 1. Report Introduction

    2. Renal cell carcinoma Market Overview at a Glance

    2.1. Total Market Share Distribution of Renal cell carcinoma for 7 MM in 2016

    2.2. Total Market Share Distribution of Renal cell carcinoma for 7 MM in 2025

    3. Renal cell carcinoma

    3.1.1. Overview

    3.1.2. Symptoms

    3.1.3. Pathophysiology

    3.1.4. Staging

    3.1.5. Diagnosis

    3.1.6. Treatment

    4. Epidemiology and Patient Population

    4.1.1. United States

    4.1.1.1. Diagnosed Cases of Renal cell carcinoma in United States

    4.1.2. Germany

    4.1.2.1. Diagnosed Cases of Renal cell carcinoma in Germany

    4.1.3. France

    4.1.3.1. Diagnosed Cases of Renal cell carcinoma in France

    4.1.4. Italy

    4.1.4.1. Diagnosed Cases of Renal cell carcinoma in Italy

    4.1.5. Spain

    4.1.5.1. Diagnosed Cases of Renal cell carcinoma in Spain

    4.1.6. United Kingdom

    4.1.6.1. Diagnosed Cases of Renal cell carcinoma in United Kingdom

    5. Treatment Algorithm

    5.1.1. Treatment Guidelines/Practices

    6. Marketed Drugs for Renal cell carcinoma

    6.1. Drug 1: Company A

    6.1.1. Drug Description

    6.1.2. Mechanism of Action

    6.1.3. Regulatory Milestones

    6.1.4. Advantages & Disadvantages

    6.1.5. Safety and Efficacy

    6.1.6. Product Profile

    6.1.7. Patent Status

    6.2. Drug 2: Company B

    6.2.1. Drug Description

    6.2.2. Mechanism of Action

    6.2.3. Regulatory Milestones

    6.2.4. Advantages & Disadvantages

    6.2.5. Safety and Efficacy

    6.2.6. Product Profile

    6.2.7. Patent Status

    7. Emerging Therapies

    7.1. Drug 3: Company C

    7.1.1. Description

    7.1.2. Regulatory Milestones

    7.1.3. Advantages & Disadvantages

    7.1.4. Product Profile

    7.1.5. Launch Date

    7.1.6. Clinical Development

    7.1.7. Clinical Pipeline Activity

    7.1.8. Ongoing Trials Information

    7.1.9. Clinical Trial by Phase

    7.2. Drug 4: Company B

    7.2.1. Description

    7.2.2. Regulatory Milestones

    7.2.3. Advantages & Disadvantages

    7.2.4. Product Profile

    7.2.5. Launch Date

    7.2.6. Clinical Development

    7.2.7. Clinical Pipeline Activity

    7.2.8. Ongoing Trials Information

    7.2.9. Clinical Trial by Phase

    8. Overview of Total Renal cell carcinoma Market (2016 & 2025)

    9. Renal cell carcinoma: Country-Wise Market Analysis

    9.1. United States

    9.1.1. Historical Market Size (2015-2016)

    9.1.2. Forecasted Market Size (2017-2025)

    9.2. Germany Market Size

    9.2.1. Historical Market Size (2015-2016)

    9.2.2. Forecasted Market Size (2017-2025)

    9.3. France Market Size

    9.3.1. Historical Market Size (2015-2016)

    9.3.2. Forecasted Market Size (2017-2025)

    9.4. United Kingdom Market Size

    9.4.1. Historical Market Size (2015-2016)

    9.4.2. Forecasted Market Size (2017-2025)

    9.5. Spain Market Size

    9.5.1. Historical Market Size (2015-2016)

    9.5.2. Forecasted Market Size (2017-2025)

    9.6. Italy Market Size

    9.6.1. Historical Market Size (2015-2016)

    9.6.2. Forecasted Market Size (2017-2025)

    9.7. Japan Market Size

    9.7.1. Historical Market Size (2015-2016)

    9.7.2. Forecasted Market Size (2017-2025)

    10. Market Drivers

    11. Market Restraints

    12. Appendix

    13. Report Methodology

    14. Consulting Services

    15. Disclaimer

    16. About DelveInsight

    List of Tables

    Table 1: Diagnosed Cases Renal cell carcinoma in United States (2015-2025)

    Table 2: Diagnosed Cases Renal cell carcinoma in Germany (2015-2025)

    Table 3: Diagnosed Cases Renal cell carcinoma in France (2015-2025)

    Table 4: Diagnosed Cases Renal cell carcinoma in United Kingdom (2015-2025)

    Table 5: Diagnosed Cases Renal cell carcinoma in Spain (2015-2025)

    Table 6: Diagnosed Cases Renal cell carcinoma in Italy (2015-2025)

    Table 7: Diagnosed Cases Renal cell carcinoma in Japan (2015-2025)

    Table 8: List of Marketed Drugs for Renal cell carcinoma

    Table 9: List of Pipeline Phase III Drugs for Renal cell carcinoma

    Table 10: Drug 1, Clinical Trials by Zone, 2017

    Table 11: Clinical Trials by Trial status, 2017

    Table 12: Drug 2, Clinical Trials by Zone, 2017

    Table 13: Clinical Trials by Trial status, 2017

    Table 14: Drug 3, Clinical Trials by Zone, 2017

    Table 15: Clinical Trials by Trial status, 2017

    Table 16: United States Market Size of Renal cell carcinoma in USD, Million (2015-2025)

    Table 17: Germany Market Size of Renal cell carcinoma in USD, Million (2015-2025)

    Table 18: France Market Size of Renal cell carcinoma in USD, Million (2015-2025)

    Table 19: United Kingdom Market Size of Renal cell carcinoma in USD, Million (2015-2025)

    Table 20: Spain Market Size of Renal cell carcinoma in USD, Million (2015-2025)

    Table 21: Italy Market Size of Renal cell carcinoma in USD, Million (2015-2025)

    Table 22: Japan Market Size of Renal cell carcinoma in USD, Million (2015-2025)

    List of Figures

    Figure 1: Diagnosed Cases Renal cell carcinoma in United States (2015-2025)

    Figure 2: Diagnosed Cases Renal cell carcinoma in Germany (2015-2025)

    Figure 3: Diagnosed Cases Renal cell carcinoma in France (2015-2025)

    Figure 4: Diagnosed Cases Renal cell carcinoma in United Kingdom (2015-2025)

    Figure 5: Diagnosed Cases Renal cell carcinoma in Spain (2015-2025)

    Figure 6: Diagnosed Cases Renal cell carcinoma in Italy (2015-2025)

    Figure 7: Diagnosed Cases Renal cell carcinoma in Japan (2015-2025)

    Figure 8: List of Marketed Drugs for Renal cell carcinoma

    Figure 9: List of Pipeline Phase III Drugs for Renal cell carcinoma

    Figure 10: Drug 1, Clinical Trials by Zone (%), 2017

    Figure 11: Clinical Trials by Trial status, 2017

    Figure 12: Drug 2, Clinical Trials by Zone (%), 2017

    Figure 13: Clinical Trials by Trial status, 2017

    Figure 14: Drug 3, Clinical Trials by Zone (%), 2017

    Figure 15: Clinical Trials by Trial status, 2017

    Figure 16: United States Market Size of Renal cell carcinoma in USD, Million (2015-2025)

    Figure 17: Germany Market Size of Renal cell carcinoma in USD, Million (2015-2025)

    Figure 18: France Market Size of Renal cell carcinoma in USD, Million (2015-2025)

    Figure 19: United Kingdom Market Size of Renal cell carcinoma in USD, Million (2015-2025)

    Figure 20: Spain Market Size of Renal cell carcinoma in USD, Million (2015-2025)

    Figure 21: Italy Market Size of Renal cell carcinoma in USD, Million (2015-2025)

    Figure 22: Japan Market Size of Renal cell carcinoma in USD, Million (2015-2025)

    Renal cell carcinoma Market (7MM)

    Renal cell carcinoma Market forecasting

    Renal cell carcinoma Sales forecasting

    Renal cell carcinoma Market segments

    Renal cell carcinoma Epidemiology

    Renal cell carcinoma Pipeline products and technologies

    Renal cell carcinoma Competitive landscape

    Renal cell carcinoma SWOT analysis

    Renal cell carcinoma Market Driver’s and barriers

    Renal cell carcinoma Key Companies and Funding

List Of Tables
in Renal cell carcinoma - Market Insights, Epidemiology and Market Forecast – 2025 [Report Updated: 10-10-2017]

Table 1: Diagnosed Cases Renal cell carcinoma in United States (2015-2025)

Table 2: Diagnosed Cases Renal cell carcinoma in Germany (2015-2025)

Table 3: Diagnosed Cases Renal cell carcinoma in France (2015-2025)

Table 4: Diagnosed Cases Renal cell carcinoma in United Kingdom (2015-2025)

Table 5: Diagnosed Cases Renal cell carcinoma in Spain (2015-2025)

Table 6: Diagnosed Cases Renal cell carcinoma in Italy (2015-2025)

Table 7: Diagnosed Cases Renal cell carcinoma in Japan (2015-2025)

Table 8: List of Marketed Drugs for Renal cell carcinoma

Table 9: List of Pipeline Phase III Drugs for Renal cell carcinoma

Table 10: Drug 1, Clinical Trials by Zone, 2017

Table 11: Clinical Trials by Trial status, 2017

Table 12: Drug 2, Clinical Trials by Zone, 2017

Table 13: Clinical Trials by Trial status, 2017

Table 14: Drug 3, Clinical Trials by Zone, 2017

Table 15: Clinical Trials by Trial status, 2017

Table 16: United States Market Size of Renal cell carcinoma in USD, Million (2015-2025)

Table 17: Germany Market Size of Renal cell carcinoma in USD, Million (2015-2025)

Table 18: France Market Size of Renal cell carcinoma in USD, Million (2015-2025)

Table 19: United Kingdom Market Size of Renal cell carcinoma in USD, Million (2015-2025)

Table 20: Spain Market Size of Renal cell carcinoma in USD, Million (2015-2025)

Table 21: Italy Market Size of Renal cell carcinoma in USD, Million (2015-2025)

Table 22: Japan Market Size of Renal cell carcinoma in USD, Million (2015-2025)

List Of Figures, Charts and Diagrams
in Renal cell carcinoma - Market Insights, Epidemiology and Market Forecast – 2025 [Report Updated: 10-10-2017]

Figure 1: Diagnosed Cases Renal cell carcinoma in United States (2015-2025)

Figure 2: Diagnosed Cases Renal cell carcinoma in Germany (2015-2025)

Figure 3: Diagnosed Cases Renal cell carcinoma in France (2015-2025)

Figure 4: Diagnosed Cases Renal cell carcinoma in United Kingdom (2015-2025)

Figure 5: Diagnosed Cases Renal cell carcinoma in Spain (2015-2025)

Figure 6: Diagnosed Cases Renal cell carcinoma in Italy (2015-2025)

Figure 7: Diagnosed Cases Renal cell carcinoma in Japan (2015-2025)

Figure 8: List of Marketed Drugs for Renal cell carcinoma

Figure 9: List of Pipeline Phase III Drugs for Renal cell carcinoma

Figure 10: Drug 1, Clinical Trials by Zone (%), 2017

Figure 11: Clinical Trials by Trial status, 2017

Figure 12: Drug 2, Clinical Trials by Zone (%), 2017

Figure 13: Clinical Trials by Trial status, 2017

Figure 14: Drug 3, Clinical Trials by Zone (%), 2017

Figure 15: Clinical Trials by Trial status, 2017

Figure 16: United States Market Size of Renal cell carcinoma in USD, Million (2015-2025)

Figure 17: Germany Market Size of Renal cell carcinoma in USD, Million (2015-2025)

Figure 18: France Market Size of Renal cell carcinoma in USD, Million (2015-2025)

Figure 19: United Kingdom Market Size of Renal cell carcinoma in USD, Million (2015-2025)

Figure 20: Spain Market Size of Renal cell carcinoma in USD, Million (2015-2025)

Figure 21: Italy Market Size of Renal cell carcinoma in USD, Million (2015-2025)

Figure 22: Japan Market Size of Renal cell carcinoma in USD, Million (2015-2025)

Additional Details

Publisher

Delve Insight

Publisher Information

DelveInsight is a leading Business Consulting and Market Research Firm. We combine industry expertise with probing market insights in innovative ways to deliver enduring results to deliver critical information to leading decision makers.



We help our clients to find answers relevant to their business, facilitating decision-making; identify potential market opportunities, competitor assessments and business environmental assessment. DelveInsight is a knowledge partner for business strategy and market research across the drug value chain.

Reference

139151 | DIMI0335

Number of Pages

70

Report Format

PDF

Delve Insight Reports

Related Reports

TitleDate PublishedPrice fromMore Details
Global Renal Failure Partnering 2010 to 2016
The Global Therapy Partnering Terms and Agreements since 2010 report provides understanding and acce...
01 Oct 2016 by Current Partnering USD $1,495 More Info
U.S. Renal Care Inc. - Pharmaceuticals & Healthcare - Deals and Alliances Profile
SummaryU.S. Renal Care Inc. (U.S. Renal Care) is a healthcare service provider that offers in-center...
10 May 2016 by Global Data USD $250 More Info
Market Access Impact: Renal Cell Carcinoma (US)
IntroductionMarket barriers boost net share for 6 major RCC treatments in US. Is your brand one of t...
01 May 2016 by FirstWord Pharma USD $4,995 More Info
Market Access Impact: Renal Cell Carcinoma (EU5)
IntroductionMarket barriers cause net share loss for 5 major RCC treatments in Europe. Is your brand...
01 May 2016 by FirstWord Pharma USD $4,995 More Info
Medical Affairs Reputations: Renal Cell Carcinoma (US)
IntroductionOpdivo’s medical affairs team working overtime to engage oncologists. Is it paying off?O...
01 Apr 2016 by FirstWord Pharma USD $5,995 More Info
Medical Affairs Reputations: Renal Cell Carcinoma (EU5)
Introduction4 medical affairs teams working hard to engage oncologists. Which one gets top marks? Eu...
01 Apr 2016 by FirstWord Pharma USD $5,995 More Info
U.S. Renal Care Inc. - Pharmaceuticals & Healthcare - Deals and Alliances Profile
SummaryU.S. Renal Care, Inc. (U.S. Renal Care) is a healthcare service provider that offers in-cente...
17 Mar 2016 by Global Data USD $250 More Info
NPS+ Renal Cell Carcinoma (US)
IntroductionTwo brands lead the RCC treatment market. How does your brand stack up?US oncologists ma...
01 Feb 2016 by FirstWord Pharma USD $2,495 More Info
NPS+ Renal Cell Carcinoma (EU5)
IntroductionCompare 8 major RCC brands. Learn which one scores 6 times higher than any other?FirstVi...
01 Feb 2016 by FirstWord Pharma USD $2,495 More Info
Renal Cell Carcinoma: KOL Insight
IntroductionWill new checkpoint inhibitors revive immunotherapy in RCC?Renal Cell Carcinoma: KOL Ins...
01 Feb 2015 by FirstWord Pharma USD $7,900 More Info

This report is published by Delve Insight

DelveInsight is a leading Business Consulting and Market Research Firm. We combine industry expertise with probing market insights in innovative ways to deliver enduring results to deliver critical information to leading decision makers.

We help our clients to find answers relevant to their business, facilitating decision-making; identify potential market opportunities, competitor assessments and business environmental assessment. DelveInsight is a knowledge partner for business strategy and market research across the drug value chain.

Download Free Report Summary PDF

Renal cell carcinoma - Market Insights, Epidemiology and Market Forecast – 2025 [Report Updated: 10-10-2017] | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...

  • Allied Market Research
  • CBR Pharma
  • Current Partnering
  • Firstword
  • Global Data
  • Global Markets Direct
  • ICD Research
  • Infinti Research Technavio
  • Marketline
  • Markets and Markets
  • Micro Markets Monitor
  • MP Advisors
  • Venture Planning Group
  • GMR Data